News

EMD Serono Launches MS-LINK Research Network to Improve Patient Care

EMD Serono, the biopharmaceutical division of Merck KGaA in the U.S. and Canada, announced the launch of the company’s Multiple Sclerosis Leadership and Innovation Network (MS-LINK), an interdisciplinary research community aimed at improving the care of individuals with multiple sclerosis (MS). The program will combine clinical outcomes…

How Diet Helped Creator of Wahls Protocol in Personal MS Journey: A Nutritionist’s View

In my recent conversation with Terry Wahls, MD, creator of the Wahls diet for multiple sclerosis (MS), she said something that resonated with me: ā€œYou canā€™t change your genes, but you can change your geneā€™s expression.ā€ How true this statement is. However, it was only a few short years ago that Dr. Wahlsā€™ diet protocol, and ā€œfood as medicineā€ philosophy was being met with strong criticism from the medical community. Nowadays, the modified paleolithic diet and lifestyle program she facilitates at the Wahls Institute in Iowa is being touted as the work of a visionary.

Ocrevus Approved in UK as First NHS Treatment for PPMS

After firstĀ rejecting it due to cost-effectiveness concerns, the National Institute for Health and Care Excellence (NICE) has now approved the use of Ocrevus (ocrelizumab) for people in the U.K. with early, inflammatory primary progressive multiple sclerosis (PPMS). This means that PPMS patients living in the…

#AANAM – Ocrevus Effective in RRMS Patients with Poor Responses to Other DMTs, Early Trial Data Suggest

Early, one-year data from theĀ Phase 3 CHORDS study show that OcrevusĀ effectively prevents relapses and disease progression inĀ relapsing-remitting multiple sclerosis (RRMS) patients who have had poor responses to other disease-modifying therapies. These interim results were presented at the 2019 annual meeting of the American Academy of NeurologyĀ (AAN) in…

#AANAM – Greater Exposure to Ocrevus Means Less Risk of Disability Progression in MS Patients, Study Contends

Higher exposure to Ocrevus (ocrelizumab) is associated with greater immune B-cell depletion in the blood, and lessened risk of disability progression in patients with relapsing multiple sclerosis (MS) and primary progressive disease (PPMS), according to new research. The study supporting that finding, ā€œPharmacokinetics, Pharmacodynamics and…

#AANAM – Scoring Tool Helps Identify Patients with RRMS or Transitioning to SPMS, Study Reports

A newly developed scoring tool enables better identification of patients with relapsing-remitting multiple sclerosis (RRMS) as well as those transitioning or already diagnosed with secondary progressive MSĀ (SPMS). The research about that finding, ā€œValidation of the Scoring Algorithm for a Novel Integrative Secondary Progressive Multiple Sclerosis (SPMS) Screening Tool,ā€…

#AANAM – Research Suggests Extended Interval Dosing of Tysabri Can Decrease Risk of PML

New data suggests that treatment withĀ TysabriĀ (natalizumab) in an extended interval dosing regimen is associated with a significantly lower risk ofĀ progressive multifocal leukoencephalopathyĀ (PML) in patients with multiple sclerosis (MS), compared with the standard interval dosing. The data was presented byĀ Lana Zhovtis Ryerson, MD, on May 7 at the 2019Ā …

Artists and MSAA Mark 10 Years of Showcasing Original Works

A bird in flight, a field of flowers, a dog surrounded by butterflies, a portrait of a toddler ā€” they’re all part of the artwork by the multiple sclerosis (MS) community done for aĀ Multiple Sclerosis Association of America (MSAA) showcasing program, now marking its 10th year. Through its…